Related Experiment Videos
Asthma severity, recommended changes of inhaled therapy and exhaled nitric oxide in children: a prospective, blinded
1Kinderpoliklinik and Kinderklinik, Dr. von Hauner Childrens' Hospital, Ludwig-Maximilians-University, Pettenkoferstr 8a, D-80336 Munich, Germany. griese@pk-i.med.uni-muenchen.de
Insights
Orally exhaled nitric oxide (ENO) in children with allergic asthma showed a weak correlation with disease severity and therapy adjustments. Further studies are needed to determine if ENO can effectively guide asthma treatment.
Area of Science:
- Pediatric Pulmonology
- Allergy and Immunology
- Biomarkers in Respiratory Disease
Background:
- Airway inflammation is a key feature of asthma.
- Orally exhaled nitric oxide (ENO) is a non-invasive marker of airway inflammation.
- The utility of ENO in guiding asthma therapy requires further investigation.
Purpose of the Study:
- To evaluate the correlation between ENO levels and asthma severity in children.
- To assess the predictive value of ENO for therapeutic decisions in pediatric allergic asthma.
- To determine if ENO can be used as a tool to direct asthma management.
Main Methods:
- Seventy-four children with allergic asthma and 31 healthy controls were enrolled.
- Asthma severity was assessed using medical history, clinical symptoms, and lung function.
- ENO was measured, but results were blinded to patients, parents, and physicians during therapeutic decision-making.
Main Results:
- ENO levels were significantly higher in asthmatic children compared to controls.
- ENO did not significantly correlate with asthma severity.
- ENO showed a weak correlation with recommended changes in inhaled therapy (r = 0.303, P = 0.009).
- ENO values above 13 ppb demonstrated moderate sensitivity (0.67) and specificity (0.65) in predicting therapy escalation.
Conclusions:
- ENO levels do not strongly correlate with asthma severity in children.
- The predictive value of ENO for guiding asthma therapy adjustments is limited.
- While ENO may offer some value, further research is essential to establish its role in directing pediatric asthma management.
Abstract:
Orally exhaled nitric oxide (ENO) correlates with several variables of airway inflammation and might be useful to direct asthma therapy. If this is true, ENO should correlate with disease severity and the therapeutic decisions made. - In 74 children with allergic asthma (age 9.7 years, range 4-16) disease severity was determined by history, clinical symptoms, and lung function and inhaled therapy was adjusted according to the NIH criteria. ENO was also measured, but the patients, their parents and the physicians who made the therapeutic decision were left unaware of the results. 31 healthy children served as controls. ENO was higher in asthmatics than in controls, but did not differ with asthma severity. ENO was weakly correlated with the changes in asthma therapy recommended (r = 0.303, P = 0.009). ENO values above normal (> 13 ppb) had a sensitivity of 0.67 and a specificity of 0.65 to predict a step up in therapy. Due to the non-normal distribution of ENO there was a substantial overlap between the different groups. The lack of correlation with disease severity and the weak prediction of physician recommended inhaled therapy, suggest that ENO may be of some value to guide asthma therapy. Studies using ENO to direct therapy are necessary for a definite answer.